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Abstract: Biomarkers of breast cancer are necessary for prognosis and prediction to chemotherapy. Prognostic biomarkers provide 
information regarding outcome irrespective of therapy, while predictive biomarkers provide information regarding response to 
therapy. Candidate prognostic biomarkers for breast cancers are growth factor receptors, steroid receptors, Ki-67, cyclins, urokinase 
plasminogen activator, p53, p21, pro- and anti-apoptotic factors, BRCA1 and BRCA2. But currently, the predictive markers are 
Estrogen and Progesterone receptors responding to endocrine therapy, and HER-2 responding to herceptin. But there are numerous 
breast cancer cases, where tamoxifen is ineffective even after estrogen receptor positivity. This lead to search of new prognostic and 
predictive markers and the number of potential markers is constantly increasing due to proteomics and genomics studies. However, most 
biomarkers individually have poor sensitivity or specificity, or other clinical value. It can be resolved by studying various biomarkers 
simultaneously, which will help in better prognosis and increasing sensitivity for chemotherapeutic agents. This review is focusing on 
growth factor receptors, apoptosis markers, signaling cascades, and their correlation with other associated biomarkers in breast cancers. 
As our knowledge regarding molecular biomarkers for breast cancer increases, prognostic indices will be developed that combine 
the predictive power of individual molecular biomarkers with specific clinical and pathologic factors. Rigorous comparison of these 
existing as well as emerging markers with current treatment selection is likely to see an escalation in an era of personalized medicines 
to ensure the breast cancer patients receive optimal treatment. This will also solve the treatment modalities and complications related 
to chemotherapeutic regimens.
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Introduction
Breast cancer is one of the most frequently diagnosed 
cancers affecting females. It is estimated that this 
disease will afflict one in eight females in America 
during their lifetime. It is estimated that occurrence 
of breast cancer is 26% of cancers from all sites. 
An estimated 40,910 (40,460 women, 450 men) breast 
cancer death rate are expected by 2007, accounting 
15% death with respect to other sites.1 Breast cancer 
is characterized by higher expression of epidermal 
growth factor receptor (EGFR) and estrogen/
progesterone receptor (ER/PR). It is also found that 
higher expression of vascular endothelial growth 
factor (VEGFR-2) is associated with metastasis and 
poor survival outcomes in breast cancer patients. The 
overexpression of either growth factors or its receptors 
leads to abnormal signaling pathways that contributes 
to the progression, invasion, and malignant phenotype. 
Patients suffering from breast carcinoma have a poor 
prognosis because of the lack of effective treatment 
strategies. Detection and identification of prognostic 
markers for predicting therapeutic response is very 
essential for breast cancer treatment. The knowledge 
of individual prognostic marker remains poorly 
understood at molecular level in breast cancer 
prognosis and prediction of particular treatment 
regimens and its overall survival. Most recently 
gene profiling helps in clustering and segregating the 
genes on the basis of prognosis of disease outcome 
and the correlation of various prognostic factors 
with metastasis, ER, HER-2 status.2,3 In a study 
of 295 patients diagnosed with stage I or II breast 
cancer, those classified as having a good prognosis 
profile had a 94.5 ± 2.6 overall 10-year survival rate 
compared to 54.6% ± 4.4% for those with a poor 
profile and the probability of remaining free of distant 
metastases was 50.6% ± 4.5% and 85.2% ± 4.3% in 
the group with poor and a good-prognosis signature4 
and thus the gene profiling can be a more valuable 
prognostic factor in predicting the disease outcome 
than the standard clinical and histogical system of 
classifications based on axillary lymph node status, 
tumor size and tumor grade.5,6 Prognostic and currently 
the predictive markers respond to endocrine therapy 
(tamoxifen and raloxifene) are ER/PR and HER-2 
for identifying breast cancer metastasis responding 
to herceptin.7 Unfortunately, a substantial number of 
tumors are intrinsically tamoxifen-resistant, despite 
estrogen-receptor positivity, and eventually almost 
all breast carcinomas acquire resistance towards 
tamoxifen. This may be due to activation or cross 
talk signaling of other growth factor/cell signaling 
pathways compensating the inhibition of upstream 
regulators of particular pathways. It can be overcome 
by designing drugs inhibiting two pathways or 
bidirectional pathways. Tumor resistance is also 
acquired due to the overexpression of ATP-binding 
cassette (ABC) transporters.8 This can be overcome 
by designing chemotherapeutic drugs inhibiting ABC 
transporters, and thus overcoming multidrug resistance 
(MDR) and sensitizing the tumors for chemotherapeutic 
drugs. Thus, the detailed understanding of cross talk 
signaling pathways between growth factor, steroid 
receptors and apoptosis regulators as well as MDR 
properties will lead to the development of new drugs 
that are sensitive and having fewer side effects.
Receptors of breast cancer
Beast cancer patients with the same diagnostic and 
clinical prognostic profile can have markedly different 
clinical and survival out-comes. This difference is 
possibly caused by the limitation of our classification 
on the basis of morphology without molecular 
classification. The differential gene expression 
patterns generated by microarray technology broadly 
classified breast cancer into two sub types ER positive 
(ER+/ErbB-2-) and ER negative (ER-/ErbB-2+). 
ER- tumors are further grouped into basal-like and 
ErbB-2 subtypes, both with poor prognosis. In contrast, 
ER+ breast cancers could be classified into luminal 
A and luminal B subtypes with significantly distinct 
prognosis, luminal A tumors displayed favorable 
outcome, whereas survival of patients with luminal B 
tumors was poor and comparable to those of the ER 
negative ErbB-2 and basal subtypes.2 The molecular 
classifications are found to be strongly associated with 
ER status and moderately associated with grade, but 
not associated with menopausal status, nodal status, 
or tumor size.3
estrogen receptor
ER can be classified into two forms ERα and ERβ, and 
mainly ERα are over-expressed around 70% breast 
cancer cases.9,10 It was found that there is alter or 
increase in expression of α and β forms of ER in tumor 
as compared to normal tissues11 and may contribute to 
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amplified estrogen response. Both α and β forms are 
homologous especially in DNA binding domain (96%) 
and hormone dependent activation function domain 
(AF-2) (56%). They have the least homology (16%) 
in hormone independent activation function domain 
(AF-1) (Fig. 1a), and probably the signaling cascade 
regulated by AF-1 may be responsible for endocrine 
irresponsive behavior of breast cancers expressing 
ERβ. Both ERα and ERβ activated estrogen response 
element (ERE) in response to estrogen and are 
inhibited with anti-estrogen.12 Estrogen binds to ER 
that lead to series of sequential events (Fig. 1b), 
finally binding to ERE present in the promoters of 
various target genes13 resulting in cell proliferation. 
ER complex can also bind to transciption factors, 
such as activator protein (AP-1) or Sp-1 that leads 
to chromatin modification by histone unwinding and 
helping in transcription of genes through alternative 
pathway. Estrogen regulated transcription at AP-1 
site acts in two different directions in case of α and β 
forms of ER. Estrogen upregulates genes regulated by 
Ap-1 mediated transcription, whereas anti-estrogen 
downregulates it and reverse is observed in case of 
β form. Subsequently, two ERs signal in different 
ways depending upon ligands and response elements. 
The different function of selective estrogen receptor 
modulators (SERMs) in breast and uterine tissues may 
also be partially contributed by hormone independent 
AF-1 and hormone dependent AF-2. There are certain 
promoters that require both AF-1 and AF-2 activity, 
whereas in other promoters both AF-1 and AF-2 
function independently. Promoters requiring AF-2 
or both AF-1 and AF-2 upregulate genes in response 
to estrogen, whereas promoters requiring only AF-1 
activity upregulate genes in response to anti-estrogen. 
It was observed by Tzukerman et al14 that tamoxifen 
(SERMs) does not activate AF-2, therefore, in tissues 
which require only AF-1 activation, tamoxifen is an 
agonist, whereas in tissues which require AF-2, or both 
AF-1 and AF-2, tamoxifen is an antagonist. Moreover, 
AF-1 region is involved in the interactions of ER 
with coactivators and repressors, further regulating 
the transcribed genes depending on the net ratio of 
coactivators and corepressors in particular tissue 
type.15,16 In addition a part of membrane ER (mER) 
is found associated with cell surface via caveolins.17 
Although classical concepts had assigned priority 
to the nuclear actions of estrogen receptor, recent 
studies document the additional importance of mER 
in mediating the rapid effects of 17-β-estradiol (E2). 
It has no transmembrane and kinase domains and is 
known to initiate E2 rapid signals by forming a protein 
complex with many signaling molecules. It mediates 
its action via G-proteins, growth factor receptor-
bound protein-2 (Grb2) and Grb2-associated binder 2 
(Gab-2), receptor tyrosine kinase (RTK) like EGFR, 
insulin like growth factor (IGF) receptor (IGFR) and 
non receptor tyrosine kinase Src.16,18 Phosphorylation 
of Ser118 at nuclear ER by mitogen-activated protein 
kinase (MAPK1/3)/extracellular signal-regulated 
kinase (ERK)17,19 or phosphatidylinositol 3-kinase 
(PI3-K)/Akt pathways lead to upregulation of estrogen 
regulated genes, whereas glycogen synthase kinase 
3 (GSK-3) inhibits the Ser118 phosphorylation of 
ER. The signaling and cross talk pathways between 
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Figure 1. Homology of eRα and eRβ. a) estrogen receptor and cross-talk 
signaling with RTK in breast cancer. b) estrogen leads to transcription 
of cell proliferation gene via classical pathway (black arrow). Cross talk 
and bidirectional (gray arrows) signaling between meR, RTK, meR and 
downstream phosphorylation of Ser118 and 167 by MAPK/eRK and 
Pi3-K/Akt pathway respectively leads to activation of estrogen regulated 
genes. GSK-3β inhibits (blocking red arrows) phosphorylation of Ser118 
which is further inactivated by Pi3-K/AKT.
Abbreviations: DBD, DNA binding domain; NLS, Nuclear localization 
sequence.
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growth factors and estrogen signaling is bidirectional. 
It is observed that prolong exposure of anti-estrogen 
irreversibly causes cells to overexpress EGFR 
mainly HER-2, and also increased binding of EGFR 
with mER. This might lead to increased signaling 
pathway of particular growth factor, decreasing 
estrogen response and hence development of anti-
estrogen resistance.20 A full understanding of the 
mechanisms underlying these relationships, with the 
ultimate aim of abrogating specific steps, should lead 
to more-targeted strategies for treatment of hormone 
dependent-breast cancer.
epidermal growth factor receptor
Epidermal growth factor receptors (EGFRs) especially 
EGFR-1 and EGFR-2 (HER-2) play role in breast 
cancer progression. EGFR family of receptors includes 
four closely related receptor tyrosine kinases (RTKs): 
EGFR/HER-1 (ErbB-1), HER-2/neu (ErbB-2), HER-3 
(ErbB-3) and HER-4 (ErbB-4). The highest degree 
of sequence homology (approximately 80% amino 
acid identity) between HER-2, EGFR and HER-4 lies 
in the tyrosine kinase domain, suggesting that this 
region is essential for the signaling function of these 
molecules. HER-3, by contrast, has four amino acids 
substitutions in its tyrosine kinase domain, leading to 
the suggestion that this receptor may have reduced or 
absent enzymatic activity and its activity is regained 
only after dimerization with other EGFRs.21 The crystal 
structure of HER receptors (HER-1, 3 and 4) are quite 
similar, having domain II-IV contacts. This prevents 
the intermolecular dimerization domain II from 
participating in homo- and heterodimerization. Ligand 
binding induces change in structural conformation; 
freeing domain II projection for receptor dimerization, 
that inturn activates RTK activity. There is no such 
contact between domain II-IV, making HER-2 always 
in active state and the preferred partners for other 
HER receptors.22–24 HER-2 overexpression has been 
reported to amplify EGFR signaling. HER-2/neu 
gene amplification is most common representing 
25%–30%25 of breast cancer of ER- type and herceptin 
shows a promising clinical result with HER-2 positive 
breast cancers. Increase in HER-2 correlates with poor 
prognosis and increased propensity for metastasis. 
HER-2 amplification results in a 50 to 100-fold 
increase in the number of surface receptors on cancer 
cells compared to the normal mammary epithelium. 
HER-2 gene amplification and oncogenic mutations 
constitutively activate the HER-2 homodimeric 
tyrosine kinase.26 Elevated HER-2 activity can reduce 
the general growth factor dependence of HER-2 
amplified cells though prolonged stimulation of the 
Ras/Raf/Mitogen-activated protein kinase (MAPK) 
pathway, and confers resistance to hormonal therapy.27 
Upon dimerization of EGFRs by EGF and Hergulin 
(HRG) and receptor phosphorylation, Shc binds the 
receptor which further transmits the signal to GRB2, 
SOS and Ras which inturn leads to an increase in Raf 
kinase activity. Once activated, Raf phosphorylates 
and activates its major substrates mitogen activated 
extracellular signal regulated kinase activating 
kinases (MEK) family which includes MEK1 and 
MEK2, which in turn phosphorylate and activate the 
MAPKs (ERK1 and ERK2). MAPK family of kinases 
also includes p38MAPK and c-Jun-N-terminal kinase 
(JNK). Inaddition to activation of Raf/MEK/ERK 
pathways, Ras and phosphorylated EGFR family 
members stimulates PI3-K activity by binding to 
p110 subunit and p85 subunit of PI3-K respectively 
(Fig. 2). Activated PI3-K phosphorylate substrates 
like phosphatidylinositol-4 phosphate and 
phosphatidylinosital 4, 5-bisphosphate to yield 3, 
4-bisphosphate [PI(3,4)P2] and phosphatidylinositol 
3,4,5-trisphosphate [PI(3,4,5)P3]. This in-turn recruits 
phosphoinositide dependent kinase-1 (PDK-1) and 
Akt family kinases to the plasma membrane and 
activate them. This signal transduction cascade 
initiated by PI3-K is referred to as the PI3-K/PDK1/
Akt pathway. This cascade can prevent apoptosis.28,29 
Although HER-2 gene amplification and protein 
overexpression have been extensively studied in breast 
cancer, data on EGFR overexpression in breast cancer 
are limited. EGFR overexpression and its activating-
mutations at exons 18–21 in lung cancers have been 
extensively studied. It has been found that there is 
a strong response of tyrosine kinase inhibitors (e.g. 
erlotinib and gefitinib) to lung cancers exhibiting EGFR 
activating-mutations. These mutations selectively 
activate AKT and signal transduction and activator 
of transcription (STAT) signaling pathways, which 
promote cell survival. Gefitinib was found to bind the 
ATP pocket of catalytic domain of EGFR kinase, and 
thus inhibiting the anti-apoptotic signals transduced 
by mutant EGFR.30 Though there is lack of data of 
EGFR activating mutations associated with breast 
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cancer, but EGFR overexpression has been reported 
to occur around 20%–36% breast cancer cases. These 
may be candidates for anti-EGFR therapies. Besides, 
there is strong synergy of EGFR with HER-2, so 
blocking both receptors may be critical. Interestingly, 
EGFR and HER-2 coexpression in breast cancer was 
recently associated with reduced overall survival 
(OS) and disease-free survival (DFS).31 It is also 
increasingly clear that the high cell-surface HER-2 
density that accompanies gene amplification alters 
the normal equilibrium of EGFR dimers in favor of 
HER-2 containing heterodimers, thus altering ligand 
dependant signaling mechanisms. The oncogenic 
potency of heterodimers, EGFR/HER-2 for example, 
is significantly enhanced compared to EGFR 
homodimers by several processes that prolong receptor 
signaling activity. HER-2/neu + breast cancer is also 
characterized by higher expression of MDR1, S100 
calcium-binding protein P, fatty acid synthase, Ras 
related GTPases, RAL-B, RAB6A, fibronectin 1, and 
syndecan1 and lower expression of c-kit and c-myc.32 
Moreover it is found that s-HER-2 elevation in early 
breast cancer correlates with the principal criteria of 
tumor aggressiveness and vascular invasion.33 It can 
act as independent prognostic factor enabling to 
identify patients likely to benefit from more aggressive 
treatments at the early stages of tumor metastasis.
vascular endothelial growth 
factor receptor
Breast cancer particularly metastatic breast cancer 
and angiogenesis is characterized by upregulation 
of VEGFR. It is a member of receptor tyrosine 
kinase family. VEGFR family of receptors consists 
of VEGFR-1 (flt-1), VEGFR-2 (KDR/flk-1) and 
VEGFR-3 (flt-4) and soluble form of VEGFR-1 
(sVEGFR-1), an intensive negative counterpart of 
VEGF.34 VEGFR-1 and VEGFR-2 is mainly responsible 
for angiogenesis whereas VEGFR-3 is responsible 
for lymphogenesis. There are common as well as 
unique ligands for VEGFRs. VEGF-A, VEGF-B 
binds to VEGFR-1. VEGF-A, VEGF-C and VEGF-
D binds to VEGFR-2. VEGF-C, VEGF-D binds to 
VEGFR-3. VEGFR-1 and VEGFR-2 are structurally 
similar, consisting of an extracellular ligand 
binding domain with seven immunoglobulin (Ig)-
like motifs, a single transmembrane domain and a 
juxtamembrane domain, a kinase domain split by 
a kinase insert, and a carboxyl terminus. Overall, 
there is 43.2% sequence homology between 
VEGFR-1 and VEGFR-2. The extracellular domain 
of VEGFR-1 and VEGFR-2 displays 33.3% 
homology and the cytoplasmic region displays 54.6% 
homology. The kinase domain of VEGFR-1 and 
VEGFR-2 represent the most conserved region with 
70.1% homology. In contrast, the carboxyl terminus 
represents the most divergent region with only 28.1% 
sequence homology. This carboxyl terminus is 
responsible for cell signaling for angiogenesis. The 
difference in sequence of carboxyl terminus between 
VEGFR-1 from that of VEGFR-2 is responsible 
for the former kinase-impaired activity. Although 
ligands have strong affinity towards VEGFR-1 than 
VEGFR-2, but it is VEGFR-2 that responds to almost 
all of the cellular responses to VEGF. Upon VEGF 
binding, receptor dimerization takes place leading 
to transphosphorylation, an increase in the intrinsic 
catalytic activity and creation of binding sites on 
the RTKs to recruit cytoplasmic signaling proteins 
that activates ERK1/2 pathway and also PI3-K/Akt 
(Fig. 2) pathways. In the unstimulated form, the 
activation loop orients tyrosine residues toward the 
activation sites of the enzyme and thereby sterically 
prevents binding to ATP-Mg2+. After binding of 
ligand and dimerization of receptors, phosphorylation 
of tyrosine residues in the catalytic loop takes place 
that orients the inhibitory loop away from the active 
site enabling the RTK to bind ATP-Mg2+. It finally 
acts as the binding sites and phosphorylates SH2- 
and PTB- containing molecules. It is found that 
solid tumors are characterized by the presence of 
hypoxic pockets, and VEGFs/VEGFRs signaling 
are responsible for survival and aggressive nature 
of tumor cells. Hypoxia induced VEGF signaling 
and constitutively activates PI3-K, stimulates Akt 
activity and hence inhibits apoptosis and favors 
cell survival. There are also reports that VEGF 
signaling can induce the expression of anti-apoptotic 
Bcl-2, Bcl-xL and promotes cell survival.35,36 In 
addition, VEGFs/VEGFRs signaling promote cell 
adhesion and migration through activated αvβ3 
integrin in breast cancer. Breast cancer cells mainly 
express VEGF-A, VEGF-B, VEGF-C and their 
receptors VEGFR-1, VEGFR-2 and neuropilin 
(NP-1/NP-2).37 VEGFR-1 is associated with poor 
prognosis, particularly those with node negative 
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tumors, with high risk of metastasis and relapse.38,39 
VEGFR-1 immunodetection may further be 
considered as a potential tool for evaluating tumor 
aggressiveness and therapeutic strategies in breast 
cancer whereas VEGFR-2 positive tumor surface 
was not correlated with survival or with metastasis 
risk and relapse.VEGFR-2 mainly functions in VEGF 
signaling whereas VEGFR-1 functions as a decoy 
receptor in VEGF signal regulation. VEGFR-3 is 
predominantly expressed in endothelium of lymphatic 
vessels. It promotes tumor lymphogenesis and 
lymphatic metastasis. VEGF-C/VEGFR-3 is also 
found in tumor tissues of breast cancer, and played 
a role in upregulating neural cell adhesion moleculer 
CNTN-1 through Src/p38 MAPK pathway.40 
It promotes cell invasion via rearrangement of actin 
cytoskeleton. Neuropilins, which are receptors for the 
collapsin/semaphorin family responsible for neural 
cell guidance, binds to VEGF (VEGF165, but not 
to VEGF121). VEGF-A secretion by breast cancer 
cell lines MDA-MB-468, T-47D, MCF-7, HBL-100, 
and MW1 were about 2.3 to 37.3 ng/ml for 106 cells 
for 48 hours, which was higher above the biological 
activity of VEGF-A (1–50 pg/ml),37 indicating 
the role of VEGF in breast cancer progression. 
VEGFR-2 phosphorylation was detected above the 
baseline in case of epithelial breast cancer cells than 
in endothelial breast cancer cell line, PAEC/KDR, 
without external VEGF stimulation. But there was 
a marked increase in VEGFR-2 phosphorylation 
following stimulation with VEGF. Weigand et al 
observed that VEGF-A-induced increase in Akt 
phosphorylation in T47D cells, while stimulation 
of MDA-MB-468, HBL-100, MCF-7 and MW1 
with VEGF-A resulted in an increase in ERK1/2 
phosphorylation. Therefore VEGF stimulation 
leads to phosphorylation of VEGFR-2 which in turn 
activates either ERK1/2 or PI3-K/Akt pathways.
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Figure 2. epidermal growth factor receptor and vascular endothelial growth factor receptor signaling in breast cancer.
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Apoptosis
Normal breast development is controlled by a 
balance between cell proliferation and apoptosis, 
and there is strong evidence that tumor growth is not 
just a result of uncontrolled proliferation but also of 
reduced apoptosis. The balance between proliferation 
and apoptosis is crucial in determining the overall 
growth or regression of the tumor in response to 
chemotherapy, radiotherapy and, more recently, 
hormonal treatments. All of these act in part by 
inducing apoptosis41–43 and inhibiting cell proliferation. 
The molecular understanding of cell proliferation and 
apoptosis signaling (Fig. 3) could allow individually 
tailored treatments to maximize tumor regression 
and its efficacy. Cancer cells overcome cell death 
or apoptosis due to mutation of tumor suppressor 
genes and impaired apoptotic machinery executing 
cell death. The apoptotic pathway is controlled 
by a diverse range of cell signals which may 
originate either extracellularly (extrinsic inducers) 
or intracellularly (intrinsic inducers). These signals 
may positively or negatively induce apoptosis. The 
extrinsic pathway is activated by binding of ligands 
such as FasL and TNF to FAS and TNFR, inducing 
the formation of death induced signaling complex 
(DISC). DISC in turn recruits caspase-8 through 
FADD (Fas-Associated Death Domain) and promotes 
the cascade of procaspase activation and finally 
RTK Fas/TNFR
SOS PI3K
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Apoptosis
Casp-7Casp-3
Apaf
cyt-c
SMAC
IAPS
Casp-3/7
Casp-9Casp-9
FADD Casp-8
P
p53
P
Bad
Bcl-XL
Bcl-2
Bad
Bax
Bax
tBid Bid
Gene expression
Cell proliferation
Casp-8
Figure 3. Apoptosis and croos-talk signaling with RTK in breast cancer.
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caspase-7 leading to apoptosis. The intrinsic pathway 
is triggered by various extracellular and intracellular 
stresses, such as growth-factor withdrawal, hypoxia, 
DNA damage and oncogene induction. Signals that 
are transduced in response to these stresses converge 
mainly on the mitochondria. A series of biochemical 
events is induced that results in the permeabilization 
of the outer mitochondrial membrane, the release 
of cytochrome-c and other proapoptotic molecules, 
the formation of the apoptosome, a large protein 
complex that contains cytochrome-c, apoptotic 
protease activating factor 1 (APAF1) and caspase-9 
and finally caspase-3/7 activation and cell death.44 
There is a cross talk between extrinsic and intrinsic 
pathway. Activated caspase-8 cleaves Bid, and the 
COOH-terminal part translocates to mitochondria 
where it triggers cytochrome-c release.45,46 Apoptosis 
is mainly governed by the net ratio of pro-apoptotic 
and anti-apoptotic Bcl-2 family members (Table 1). 
Higher Bax/Bcl-2 ratio predicts good response for 
chemotherapy in breast cancers, indicating apoptosis. 
There are at least 19 Bcl-2 family members that have 
been identified in mammalian cells, with several 
others found in viruses.47 They possess at least one of 
the four conserved motifs known as Bcl-2 homology 
domains (BH1 to BH4).48,49 Most anti-apoptotic 
members contain all four of these domains. Some 
pro-apoptotic Bcl-2 family proteins possess only the 
BH3 domain, which is essential for their function,50,51 
indicating the role of BH3 domain in apoptosis. 
These pro- and apoptotic Bcl-2 family members 
will be studied in detail to understand and unveil the 
chemoresistance in breast cancers.
Apoptosis regulators
Prognostic markers of breast cancers (Table 2) include 
apoptotic regulators, growth factors, proteases and 
topoisomearse. Apoptotic regulation is controlled 
by Bcl-2 family of proteins. The expression of 
Bcl-2 protein has been shown to suppress apoptosis 
in response anticancer drugs.52,53 Therefore, Bcl-2 
may mediate chemoresistance in some patients and 
Bcl-2 could be a target for the development of 
new anticancer therapy. Inhibition of expression of 
Bcl-2 family members by antisense oligonucleotide 
or dominant negative inhibitor Bcl-xs has already 
been shown to promote apoptosis and to sensitize 
cells to chemotherapy-induced apoptosis.54 Despite 
the antiapoptotic and chemoresistant effects favoring 
tumor survival, Bcl-2 prolongs cell cycle and 
decreases tumor cell proliferation, and these functions 
may account for the association of Bcl-2 in favorable 
breast cancer outcomes. In humans Bcl2 is expressed 
in about 80% of breast cancers55,56 in women with 
primary tumors, having either node positivity or 
negativity and is correlated with the expression of ER 
and PR. Zhang et al57 observed that Bcl-2 gradually 
decreases during the development of breast cancer, 
i.e. from a normal epithelium (96%) to intraductal 
carcinoma (79%), and from intraductal to invasive 
carcinoma (45%), and reverse is observed in case 
of p53 expression. Consistent with these findings, 
Haldar et al58 reported that transfection of mutant 
p53 into a p53-wild-type breast cancer cell line 
suppressed expression of Bcl-2. Major correlations 
between Bax protein and outcome have not been 
observed, although in patients with breast cancer, 
a reduced expression of Bax was correlated with a 
poor response to chemotherapy and metastatic breast 
cancer.59,60 Restoration of Bax expression in breast 
cancer cell lines increased sensitivity to cytotoxic 
drug therapy and also suppressed tumorigenesis.61,62 
However, in breast cancers, no correlation between 
the percentages of Bax and p53-immunopositive 
tumor cells was observed when examined as either 
dichotomous or continuous variables, although 
p53 binds with Bax gene promoter and hence 
Table 1. Bcl-2 family members.
Anti-apoptotic pro-apoptotic
BCL-2 BAX
BCL-XL BAK
MCL-1 BOK
A-1/BFL-1 BAD
BCL-w BiD
BOO/DivA BiK
NR-13 BLK
HRK
BiM
BNiP3
NiX
NOXA
esteva and Hortobagyi.47
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acts as transcriptional activator.63 Moreover Bax 
immunostaining was not significantly correlated 
with HER-2, cathepsin D or S phase fraction, but 
was positively associated with Bcl-2. The other 
antiapoptotic proteins related to Bcl-2 are Bcl-xL 
and Mcl-1. The remarkable structural similarity 
between the Bcl-2 and Bcl-x genes suggests that they 
have evolved from a common ancestral gene by way 
of gene duplication.64 Through alternate splicing, 
Bcl-x can encode several proteins, including the 
Bcl-xL (long) protein which inhibits apoptosis and 
a shorter isoform Bcl-xS which promotes apoptosis 
by acting as a trans-dominant inhibitor of Bcl-2 and 
Bcl-xL. Bcl-xL inhibits cytochrome-c redistribution 
from inter membrane space of mitochondria to cytosol 
by blocking both membrane hyperpolarization and 
mitochondrial swelling in response to several sets of 
apoptotic stimuli.65 Moreover, recent studies report 
that Bcl-xL protein interacts with Apaf-1 to inhibit the 
caspase activation involved in apoptosis,66 increases 
metastatic potential of breast cancer. Increased levels 
of Bcl-xL expression were found in a subset of primary 
human breast carcinomas, mainly in undifferentiated 
histological grade (HG) III tumors.67,68 In the breast, 
their overexpression could protect breast cancer cells 
from p53-mediated apoptosis.69 More recently BAG-1, 
a multi functional protein that blocks apoptosis, has 
been correlated with improved survival in early stage 
breast cancer. Again, this seemingly contradictory 
finding in an inhibitor protein reflects the complex 
mechanisms in which these proteins work; BAG-1 is 
known to interact with other members of the Bcl-2 
family as well as heat shock proteins and estrogen 
receptors. Another member of pro-apoptotic Bcl-2 
family consists of Bad that bind to anti-apoptotic Bcl-2 
and Bcl-xL, thus induce apoptosis. In fact, in normal 
human breast cells, Bad levels are relatively high in 
comparison with those in other organs,70 suggesting 
that Bad might have a special role in the breast. Bad is 
regulated by growth factors and cytokines, stimulating 
Bad phosphorylation on specific serine residues: 
S112, S136, S155 and S170. Phosphorylation of 
Bad on these residues promotes its binding to, 
and subsequent cytosolic sequestration by, 14-3-3 
proteins. Thus phosphorylation at serine residues 
prevents Bad from associating with Bcl-2 or Bcl-xL 
on the mitochondrial outer membrane, leaving these 
proteins free to exert their anti-apoptotic function.71 
Indeed, Gilmore et al72 showed that transient Bad 
overexpression enhances the sensitivity of mammary 
Table 2. Bio-molecular markers of breast cancers.
Markers Occurrence (%) Treatment References
eGFR 17% Chemotherapy 97
HeR-2 25% Monoclonal Humanized antibody 25,76
veGFR 64% (invasive  
breast cancer)
Chemotherapy 34,98
eR and PR 70%–80% endocrine therapy 99,10
BRCA1 and BRCA2 2%–4% Chemotherapy and Radiotherapy 100
P53 25%–30% Chemotherapy 101–103
P21 (10% of cells positive) 65% Chemotherapy 104
Bcl-2 80% Chemotherapy, antisense RNA 55,56
Topoisomerase ii α 50.2% Chemotherapy: Anthracycline 105
uPA and PAi-1 46% Adjuvant chemo or endocrine therapy 106,107
Caspase-3 75.2% Chemotherapy 108
*TiP30/CC3 83.3% Genetherapy 109,110
**Ki-67 56% Chemotherapy and endocrine therapy 111,112
*TiP30/CC3 is metastatic tumor suppressor gene. Decrease in expression of TiP30 is observed in 48% of breast cancer cases and 83.3% of TiP30 
negativity tumors had lymph node metastasis and vascular invasion. **Ki-67 cut off value for primary (P) tumors is 10% and 15% for metastatic (M) tumors. 
P-/M- = 44%, P+/M+ = 27.3%, 14%, P-/M+ = 21.1%, P+/M- = 7.2%.
Abbreviations: uPA, urokinase plasminogen activator; PAi-1, plasminogen activator inhibitor-1.
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cells to apoptosis, perhaps because the S112 and S136 
kinases become limiting. On the other hand, primary 
cultures of Bad-/- mammary cells are no longer 
sensitive to ZD1839-induced apoptosis, suggesting 
that Bad might be the important pro-apoptotic effector 
downstream of the EGFR. Survivin, a member of the 
inhibitor of apoptosis (IAP) gene family, containing 
only a single baculoviral IAP repeat (BIR) domain. 
Survivin is overexpressed in most human cancers, 
including breast, but is not expressed in normal 
tissue. 84% of breast carcinoma showed nuclear 
survivin expression.73 Survivin is associated with 
more aggressive behavior and decreased survival in 
a variety of tumor types. It regulates the G2/M phase 
of the cell cycle by associating with mitotic spindle 
microtubules, and it directly inhibits caspase-3 and 
caspase-7 activity. There is a gradual rise in the 
expression of caspases 3, 6 and 8 and the expression 
of these caspases are strongly associated with increase 
in apoptosis, with a direct relationship between the 
apoptotic index and the histological aggressiveness of 
a breast lesion.74 Expression of genes such as p53 and 
c-erb-B2 are also increased in higher grade tumors. 
It is possible that such genes may be responsible 
for the increased apoptotic rate observed in these 
tumors.
Molecular targets and chemotherapeutic 
drugs
Breast cancer is characterized by overexpression of 
ER/PR, EGFR, HER-2 and VEGFR-2, along with 
Bcl-2 and downreguation of p53. At present, the 
circle of agents with an established chemopreventive 
effect is restricted to tamoxifen and raloxifene 
in breast cancer. However, in recent years, there 
has been an exponential increase in the study of 
agents (Table 3) that have a chemopreventive 
potential against molecular targets of breast cancer. 
The treatment for cancer cells that may have spread 
beyond the breast, lymph nodes and nearby tissues 
is a combination of either hormone therapy (anti-
estrogen) and/or chemotherapy. Metastatic breast 
cancer (MBC) develops in 30%–40% of patients with 
breast carcinoma and patients with MBC have a median 
survival of about 2 years and, therefore, new anticancer 
agents are urgently required.75 Chemotherapeutic 
drugs are applied to patients depending upon size, 
lymph node status, ER and PR, and HER-2/neu 
over-expression. Herceptin is a monoclonal antibody 
targeting HER-2 overexpression breast cancer cells. 
It induces HER-2 receptor downmodulation and, 
as a result, inhibits Ras/Raf/MAPK and PI3-K/Akt 
pathways leading to inhibition of cell proliferation and 
apoptosis and also blocking cell cycle progression by 
inducing the formation of p27/Cdk2 complexes.25,76,77 
It is found that addition of herceptin along with 
other chemotherapeutic drugs for early stage HER-2 
positive breast cancers reduced the risk of recurrence 
and death by 52% and 33% respectively, compared to 
chemotherapy alone.78,79 There is another humanized 
monoclonal antibody, pertuzumab (2C4) that binds 
to different epitope than that of herceptin. It mainly 
inhibits HER-2 heterodimerization with HER-1, 
HER-3 and HER-4 and thus inhibits downstream cell 
proliferation pathways of HER-2 based heterodimers 
in cells with low or high expression of HER-2 
receptors.25 Bevacizumab (Avastin) is a monoclonal 
antibody against VEGF, thus help in inhibiting in 
angiogenesis. It is approved by FDA in 2008 and 
used in metastatic breast cancer as adjuvant therapy 
along with 5- florouracil (5-FU), oxaliplatin. The 
most common chemotherapeutic drugs recommended 
to be used in combination in early breast cancer 
are cyclophosphamide, methotrexate, fluorouracil, 
Table 3. Drugs used for breast cancer treatment.
Drugs Molecular targets
Tamoxifen eR
Raloxifene eR
Steroidal Ai: exemstane Aromatase/estrogen
Non-steroidal Ai: 
Anastrozole and 
Letrozole
Aromatase/estrogen
Herceptin HeR-2
Pertuzumab HeR-2
Bevacizumab veGF/veGFR
Gefitinib eGFR
Zactima veGFR/eGFR
Doxorubicin DNA, Topoisomerase ii 
complex
Taxane  
(Paclitaxel, docetaxel)
β subunit of tubulin, Bcl-2
5-Fluorouracil, 
capecitabine (prodrug)
Thymidylate synthase
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doxorubicin (adriamycin), epirubicin, paclitaxel 
(Taxol), and docetaxel (Taxotere). Paclitaxel (PAC) 
and docetaxel (DOC) are clinically effective anti 
neoplastic agents and excellent choices for the 
first- and second-line treatment of patients with 
MBC.80,81 Taxanes bind to β-subunit of tubulin, retard 
microtubule depolymerization, impair mitosis, and 
block progression through the cell cycle. In addition, 
the taxanes inactivate the Bcl-2 protein and induce 
apoptosis in breast cancer cells in vitro.82,83
Better understandings of breast cancer at 
molecular level helps in designing new potential 
anticancer drugs that target specific receptors and 
tumors, thus increasing the efficiency and having 
lesser side effects than conventional chemotherapy. 
Such targeted therapies as adjuvant therapy benefits 
the patients in advanced diseases, delay the time 
of cancer reoccurrence as well as reverses the 
hormone- and chemo-resistance. Lapatinib, a dual 
tyrosine kinase inhibitor of EGFR and HER-2, inhibits 
autophosphorylation of tyrosine kinase residue and 
exerts greater biologic effects in inhibiting signaling 
pathways of cell proliferation and inducing apoptosis 
than inhibition of either receptor alone.84 It has 
been approved by FDA in 2007 for use in patients 
with advanced metastatic breast cancer along with 
chemotherapeutic drugs like taxanes, herceptin, 
and capecitabine. It is effective in delaying cancer 
progression in HER-2 positive advanced metastatic 
breast cancer women who have become resistant to 
Herceptin.85 There is another class of drugs that fall 
under hormone therapy. They can be further divided 
into selective estrogen receptor modulators (SERMs) 
and aromatase inhibitors (AIs). Tamoxifen (Nolvadex) 
and raloxifene compete with estrogen in binding ER. 
Upon binding the receptor complex may act as agonist 
by binding with co-activators and enhance the 
estrogenic signaling responses or antagonist by 
binding with co-repressors and thus inhibiting the 
estrogenic responses. Moreover the outcome of the 
response is also governed by the type of tissue and 
the RTK by enhancing the estrogenic responses. Thus 
the final outcome is governed by the balance between 
antagonist and agonist effect of SERMs.86 Tamoxifen 
is used in ER+ metastatic breast cancer as adjuvant 
therapy in a pre and post menopausal women. It is 
cytostatic drug leads to accumulation at G0/G1 
phase perhaps by forming the complex p21/CDK2.87 
Tamoxifene also leads to endometrial cancer after 
prolong use, whereas raloxifene doesn’t and it is as 
effective as tamoxifene and used in treating ER+ 
invasive breast cancer patients with postmenopausal 
osteoporosis.88,89 AIs include anastrozole (Armidex), 
letrozole (Femara) and exemestane (Aromasin). AIs 
block the conversion of androstenedione into estrogen 
and are found to be more effective than tamoxifen in 
treating post menopausal women with ER+ breast 
cancers.90–92 Though, lot of cytotoxic drugs is available, 
but still challenges in treatment remains. Many tumor 
cells become resistant to commonly used cytotoxic 
drugs due to the overexpression of ABC transporters. 
Two proteins, P-gp (MDR-1, ABCB1) and MRP-1 
(ABCC1) have been demonstrated to pump a wide 
selection of the most commonly used anti-cancer 
drugs and their overexpression correlates broadly 
with negative treatment response characteristics in 
many different forms of cancer. It is also found that 
genetic alteration or gene amplification of metastasis 
gene metadherin (MTDH) is associated with more 
than 40% breast cancer cases with poor clinical 
outcomes.93 These findings establish that anticancer 
drugs targeting ABC transporters and MTDH can be 
used in increasing the chemotherapeutic efficacy and 
reducing metastasis risk.
conclusions
The prognosis and over all survival of breast cancer 
has improved over years, with current 10 year relative 
survival of about 70% in western population.94,95 
Positive lymph node status, tumor size, PR and ER, 
HER-2 are the most reliable prognostic factors in 
predicting overall as well as disease free survival of 
breast cancer patients.96 The knowledge of individual 
prognostic marker remains poorly understood at 
molecular level in breast cancer prognosis and 
prediction of particular treatment regimens and its 
overall survival. Gene profiling, the future diagnostic 
tool, help in clustering and segregation of genes based 
on disease outcome and correlation with established 
biomarkers ER/PR and HER-2. It has the potential 
to find new biomarkers and solve the molecular basis 
of chemoresistance. It is expected that more patient 
samples and gene profiling datas will help in validation 
of various prognostic factors i.e. EGFR-1, cell cycle 
molecules, apoptosis related proteins, VEGF, sVEGFR, 
matrix metalloproteinase (MMP)-2 and MMP-9, 
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tissue inhibitors of metalloproteinases, plasminogen 
activators and inhibitors, etc. that are currently in 
investigation for primary and advanced breast cancer. 
The increasing number of biomarkers associated with 
breast cancers should yield a better test for prognosis 
and thus increase the screening sensitivity between 
healthy and cancer at early stages. Moreover, it’ll also 
help in designing cancer therapies and drugs that are 
tailored to unique characteristics of each individual and 
tumor. Such rational therapies will have less adverse 
effects than conventional therapy and will have better 
outcome in overall and disease free survival.
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